Display options
Share it on

Gland Surg. 2015 Aug;4(4):307-11. doi: 10.3978/j.issn.2227-684X.2015.06.05.

A cost analysis of thyroid core needle biopsy vs. diagnostic surgery.

Gland surgery

Pierpaolo Trimboli, Naim Nasrollah, Stefano Amendola, Anna Crescenzi, Leo Guidobaldi, Carlo Chiesa, Riccardo Maglio, Giuseppe Nigri, Alfredo Pontecorvi, Francesco Romanelli, Laura Giacomelli, Stefano Valabrega

Affiliations

  1. 1 Section of Endocrinology and Diabetology, Ospedale Israelitico, Rome, Italy ; 2 Section of Surgery, Ospedale Israelitico, Rome, Italy ; 3 Pathology Unit, Campus Bio-medico University Hospital, Rome, Italy ; 4 Section of Pathology, Ospedale Israelitico, Rome, Italy ; 5 Department of Surgical Sciences, Sapienza University, Rome, Italy ; 6 Department of Surgical and Medical Sciences, Sapienza University, Ospedale S. Andrea, Rome, Italy ; 7 Institute of Endocrinology, Catholic University of Rome, 00168 Rome, Italy ; 8 Department of Experimental Medicine, Sapienza University, Rome, Italy.

PMID: 26312216 PMCID: PMC4523622 DOI: 10.3978/j.issn.2227-684X.2015.06.05

Abstract

BACKGROUND: Twenty percent of thyroid fine needle aspiration (FNA) is indeterminate. Because 3 in 4 of these are actually benign, a method of clarifying the pathology could help patients to avoid diagnostic thyroidectomy. Recently, core needle biopsy (CNB) has been proven to be highly reliable for this purpose. However, there are no reports of any potential cost benefit provided by CNB. Here we analyzed the impact on management costs of CNB compared with traditional diagnostic surgery in indeterminate FNA.

METHODS: Over 24 months, 198 patients with thyroid indeterminate cytology underwent CNB at Ospedale Israelitico of Rome or diagnostic surgery at the Department of Surgery of Sapienza University of Rome. We tabulated costs of the medical instruments, operating theater, surgical team, patient recovery, and pathologic examination for each method.

RESULTS: In CNB group, 42.4% of patients had benign lesions and avoided surgery, 20.8% was cancer, and the remaining 36.8% uncertain. The malignancy rate in CNB group was 26.4%, and mean cost of CNB per nodule was 1,032€. In diagnostic surgery group, 24.7% had cancer and 75.3% had benign lesions, and mean expense for each thyroidectomy was 6,364€. In an ideal cohort of 100 patients with indeterminate FNA, the cost of CNB is 33.8% lower than that of diagnostic surgery.

CONCLUSIONS: CNB can detect a large proportion of the benign thyroid nodules that are classified as indeterminate by FNA. These patients can avoid diagnostic thyroidectomy and hospitals can reduce their surgical costs by one-third.

Keywords: Thyroid; core needle biopsy (CNB); cost-effectiveness; cytology; surgery

References

  1. Endocrine. 2013 Jun;43(3):659-65 - PubMed
  2. Thyroid. 1998 Jul;8(7):565-9 - PubMed
  3. Diagn Cytopathol. 2009 Oct;37(10):783-5 - PubMed
  4. Lancet Oncol. 2008 Jun;9(6):543-9 - PubMed
  5. Endocr Relat Cancer. 2005 Jun;12(2):305-17 - PubMed
  6. J Endocrinol Invest. 2010;33(5 Suppl):51-6 - PubMed
  7. Endocrine. 2014 Feb;45(1):79-83 - PubMed
  8. Thyroid. 2009 Nov;19(11):1159-65 - PubMed
  9. J Clin Endocrinol Metab. 2014 Oct;99(10):3700-7 - PubMed
  10. Thyroid. 2012 May;22(5):468-75 - PubMed
  11. Endocrine. 2015 May;49(1):191-5 - PubMed
  12. Thyroid. 2006 Feb;16(2):109-42 - PubMed
  13. Eur Radiol. 2012 Jul;22(7):1564-72 - PubMed
  14. Head Neck. 2011 Feb;33(2):160-5 - PubMed
  15. Radiology. 2003 Mar;226(3):827-32 - PubMed
  16. Cancer. 2008 Dec 25;114(6):512-8 - PubMed
  17. Endocrine. 2015 Nov;50(2):335-43 - PubMed
  18. Endocrine. 2014 May;46(1):52-9 - PubMed
  19. Endocrine. 2015 Apr;48(3):779-85 - PubMed
  20. J Endocrinol Invest. 2014 Jun;37(6):593-9 - PubMed
  21. Clin Endocrinol (Oxf). 2014 Jul;81 Suppl 1:1-122 - PubMed
  22. Endocrine. 2013 Aug;44(1):70-8 - PubMed

Publication Types